As HPV-vaccinated cohorts age into screening eligibility, researchers evaluated how cervical cancer screening intensity could be tailored by age at vaccination and vaccine type to balance benefits, harms,...
In a phase 3 randomized trial of women with stage I-III breast cancer, a low-glycemic Mediterranean diet, brisk walking, and vitamin D did not reduce recurrence overall but improved weight and metabolic...
In a propensity-matched analysis of stage I-III solid tumors, GLP-1 receptor agonist exposure after cancer diagnosis was associated with lower metastatic progression in several cancer types. These findings...
In a retrospective national VA cohort of nearly 1 million Veterans, tobacco smoking duration criteria identified more screening-eligible patients and fewer missed lung cancer diagnoses than pack-year...
In the phase 3 PEAK trial, bezuclastinib plus sunitinib significantly improved median progression-free survival vs sunitinib alone in patients with advanced gastrointestinal stromal tumors after prior...
In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...
In an integrated phase 2 analysis of HPV-associated oropharyngeal cancer, FMISO PET-guided chemoradiotherapy de-escalation was associated with 97% 5-year overall survival in both the 30-Gy and 70-Gy...
The FDA approved Enhertu for neoadjuvant treatment of adults with HER2-positive stage II or III breast cancer and adjuvant treatment of patients with residual invasive disease after neoadjuvant therapy.
...
The FDA approved oral decitabine and cedazuridine (Inqovi) tablets with venetoclax for adults with newly diagnosed acute myeloid leukemia who are aged 75 years or older or have comorbidities that preclude...
